Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Salgado

Showing results (201-210 of 277) with videos related to

Pageof 28
Sort By:
The Journal of Clinical Investigation|June 20, 2013
CD4⁺ follicular helper T cell infiltration predicts breast cancer survivalChunyan Gu-Trantien, Sherene Loi, Soizic Garaud, et al.
Nature Medicine|May 29, 2020
Geospatial immune variability illuminates differential evolution of lung adenocarcinomaKhalid AbdulJabbar, Shan E Ahmed Raza, Rachel Rosenthal, et al.
JAMA Oncology|September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical TrialDebora Fumagalli, David Venet, Michail Ignatiadis, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 29, 2025
Aboriginal and Torres Strait Islander females and survival from breast cancerAlice R T Bergin, Luc Te Marvelde, Roger L Milne, et al.
Ebiomedicine|July 26, 2022
Timing evolution of lobular breast cancer through phylogenetic analysisDanai Fimereli, David Venet, Mattia Rediti, et al.
Journal of the National Cancer Institute|February 23, 2018
Immune Infiltration in Invasive Lobular Breast CancerChristine Desmedt, Roberto Salgado, Marco Fornili, et al.
Nature Communications|January 30, 2016
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyDouglas B Johnson, Monica V Estrada, Roberto Salgado, et al.
Journal of the National Cancer Institute|March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast CancerRim S Kim, Nan Song, Patrick G Gavin, et al.
Nature Communications|November 4, 2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trialsMattia Rediti, Aranzazu Fernandez-Martinez, David Venet, et al.
Nature Genetics|October 2, 2024
MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolutionClare Puttick, Thomas P Jones, Michelle M Leung, et al.
Pageof 28

Showing results (201-210 of 277) with videos related to

Sort By:
Pageof 28
The Journal of Clinical Investigation|June 20, 2013
CD4⁺ follicular helper T cell infiltration predicts breast cancer survivalChunyan Gu-Trantien, Sherene Loi, Soizic Garaud, et al.
Nature Medicine|May 29, 2020
Geospatial immune variability illuminates differential evolution of lung adenocarcinomaKhalid AbdulJabbar, Shan E Ahmed Raza, Rachel Rosenthal, et al.
JAMA Oncology|September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical TrialDebora Fumagalli, David Venet, Michail Ignatiadis, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 29, 2025
Aboriginal and Torres Strait Islander females and survival from breast cancerAlice R T Bergin, Luc Te Marvelde, Roger L Milne, et al.
Ebiomedicine|July 26, 2022
Timing evolution of lobular breast cancer through phylogenetic analysisDanai Fimereli, David Venet, Mattia Rediti, et al.
Journal of the National Cancer Institute|February 23, 2018
Immune Infiltration in Invasive Lobular Breast CancerChristine Desmedt, Roberto Salgado, Marco Fornili, et al.
Nature Communications|January 30, 2016
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyDouglas B Johnson, Monica V Estrada, Roberto Salgado, et al.
Journal of the National Cancer Institute|March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast CancerRim S Kim, Nan Song, Patrick G Gavin, et al.
Nature Communications|November 4, 2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trialsMattia Rediti, Aranzazu Fernandez-Martinez, David Venet, et al.
Nature Genetics|October 2, 2024
MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolutionClare Puttick, Thomas P Jones, Michelle M Leung, et al.
Pageof 28